Day One Biopharmaceuticals Inc (NASDAQ:DAWN) has a beta value of -1.26 and has seen 1.29 million shares traded in the last trading session. The company, currently valued at $666.95M, closed the last trade at $6.58 per share which meant it gained $0.13 on the day or 2.02% during that session. The DAWN stock price is -160.49% off its 52-week high price of $17.14 and 4.86% above the 52-week low of $6.26.
The consensus among analysts is that Day One Biopharmaceuticals Inc (DAWN) is Buy stock at the moment, with a recommendation rating of 1.22. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information
Sporting 2.02% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the DAWN stock price touched $6.58 or saw a rise of 12.5%. Year-to-date, Day One Biopharmaceuticals Inc shares have moved -48.07%, while the 5-day performance has seen it change -12.03%. Over the past 30 days, the shares of Day One Biopharmaceuticals Inc (NASDAQ:DAWN) have changed -2.66%.
Wall Street analysts have a consensus price target for the stock at $40, which means that the shares’ value could jump 83.55% from current levels. The projected low price target is $24.0 while the price target rests at a high of $45.0. In that case, then, we find that the current price level is -583.89% off the targeted high while a plunge would see the stock gain -264.74% from current levels.
Day One Biopharmaceuticals Inc (DAWN) estimates and forecasts
The company’s shares have lost -57.36% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -38.09% over the past 5 years.
DAWN Dividends
Day One Biopharmaceuticals Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s Major holders
The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 7.87 million shares worth more than $108.47 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 9.0354% of shares outstanding.
The other major institutional holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, with the holding of over 6.43 million shares as of 2024-06-30. The firm’s total holdings are worth over $88.61 million and represent 7.3808% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Securities Fund-Fidelity Small Cap Growth Fund . As of Dec 31, 2024 , the former fund manager holds about 2.21% shares in the company for having 2.24 shares of worth $14.71 million while later fund manager owns 1.59 shares of worth $10.47 million as of Feb 28, 2025 , which makes it owner of about 1.57% of company’s outstanding stock.
